- Research article
- Open Access
- Open Peer Review
In vitro and in vivo characterization of highly purified Human Mesothelioma derived cells
- Alice Melotti†1,
- Antonio Daga†2,
- Daniela Marubbi1, 2,
- Annalisa Zunino2,
- Luciano Mutti3 and
- Giorgio Corte1, 2Email author
© Melotti et al; licensee BioMed Central Ltd. 2010
- Received: 17 July 2009
- Accepted: 22 February 2010
- Published: 22 February 2010
Malignant pleural mesothelioma is a rare disease known to be resistant to conventional therapies. A better understanding of mesothelioma biology may provide the rationale for new therapeutic strategies. In this regard, tumor cell lines development has been an important tool to study the biological properties of many tumors. However all the cell lines established so far were grown in medium containing at least 10% serum, and it has been shown that primary cell lines cultured under these conditions lose their ability to differentiate, acquire gene expression profiles that differ from that of tissue specific stem cells or the primary tumor they derive from, and in some cases are neither clonogenic nor tumorigenic. Our work was aimed to establish from fresh human pleural mesothelioma samples cell cultures maintaining tumorigenic properties.
The primary cell cultures, obtained from four human pleural mesotheliomas, were expanded in vitro in a low serum proliferation-permissive medium and the expression of different markers as well as the tumorigenicity in immunodeficient mice was evaluated.
The established mesothelioma cell cultures are able to engraft, after pseudo orthotopic intraperitoneal transplantation, in immunodeficient mouse and maintain this ability to after serial transplantation. Our cell cultures were strongly positive for CD46, CD47, CD56 and CD63 and were also strongly positive for some markers never described before in mesothelioma cell lines, including CD55, CD90 and CD99. By real time PCR we found that our cell lines expressed high mRNA levels of typical mesothelioma markers as mesothelin (MSLN) and calretinin (CALB2), and of BMI-1, a stemness marker, and DKK1, a potent Wingless [WNT] inhibitor.
These cell cultures may provide a valuable in vitro and in vivo model to investigate mesothelioma biology. The identification of new mesothelioma markers may be useful for diagnosis and/or prognosis of this neoplasia as well as for isolation of mesothelioma tumor initiating cells.
- Cancer Stem Cell
- Malignant Pleural Mesothelioma
- Stem Cell Marker
- Malignant Mesothelioma
- Immunodeficient Mouse
Malignant mesothelioma is an aggressive neoplasm arising from the surface serosal cells of the pleural, peritoneal, and pericardial cavities. Asbestos exposure has been established as the primary cause of mesothelioma; however, there is a long latency period of 30-45 years between exposure to asbestos and development of disease. Workers in the shipyard industry, insulation workers, construction workers, and asbestos miners and manufacturers seem to be at highest risk for developing the disease. Many investigators have suggested that Simian virus 40 (SV40), originating from contaminated poliovirus vaccines that were administered in USA and some European countries between 50's and 70's, might function as a cocarcinogen involved in the development of the disease. However, the relationship between SV40 and mesothelioma remains uncertain . Other findings suggest at least a cooperative carcinogenic effect of SV40 and asbestos in mesothelioma development [2, 3]. The male to female ratio is about 4:1 . Mesothelioma is a relatively rare disease. The incidence of mesothelioma in Western Europe, and has been steadily rising over the last 40 years, and now is of about 5000 cases per year. It is expected to reach a peak approximately in 2020, and the decrease over the next 50-60 years as a result of the implementation of rules to reduce workplace exposure to asbestos. Malignant pleural Mesothelioma (MM) most commonly develops in the fifth to seventh decade of life, with a median age of 60 years at diagnosis. The most common symptoms at diagnosis are dyspnea and nonpleuritic chest pain. Several prognostic factors have been identified in MM. Poor prognostic variables include: nonepithelial histology, older age (greater than 75 years), pleural primary, chest pain at presentation, poor performance status and elevated platelet count (greater than 400,000/mcL). The median survival is in the range of 4-18 months. Current therapies include surgery, radiation therapy, chemotherapy, and multimodality therapy, but have yielded disappointing results . It is hoped that a better understanding of MM biology may provide the rationale for new therapeutic strategies. In this regard, the development of tumor cell lines has been an important tool to study the biological properties of many tumors. However, only few mesothelioma cell lines have been established [6–10]. There is no specific marker for mesothelioma and antibodies that recognize molecules expressed by mesothelial cells and mesothelioma have limited specificity.
A cancer stem cell population in malignant tumors plays an essential role in tumor initiation, growth and recurrence [11, 12]. It was demonstrated that cancer stem cells, capable of self-renewal and multilineage differentiation, are present in blood and solid tumors [13–15]. This clonogenic tumoral subpopulation is the only one able to originate a tumor mass containing the variety of differentiated cells present within the original tumor and, for this reason, these cells were described as cancer stem cells. This term may cause confusion, suggesting that the cell of origin is a normal stem cell, a question still unresolved. For this reason we prefer the term "tumor-initiating cells" or TICs, as opposed to the non-tumorigenic cancer cells.
Until now the presence of TICs in MM tumors has not been demonstrated. Moreover all the primary cell lines isolated so far were grown in medium containing at least 10% serum, and it was demonstrated that primary cells cultured under these high serum conditions lose their self-renewing properties, have no ability to differentiate, exhibit gene expression profiles that are different from tissue specific stem cells or the primary tumor they were derived from, and in some cases are neither clonogenic nor tumorigenic .
To obtain a better MM in vitro and in vivo model, we established MM cultures from fresh human pleural mesothelioma surgical specimens. The primary cell lines were expanded in vitro in a low serum proliferation-permissive medium and the expression of different markers as well as the tumorigenicity in immunodeficient mice was evaluated.
Patients and MM TICs culture
MM specimens were obtained from the Pneumology, Spedali Civili (Brescia, Italy) and the Villa Scassi Hospital (Genova Sampieradarena, Italy). Informed consent was obtained for all patients as approved by the Ethics Board. Pathologists diagnosed malignant Mesothelioma. Of the 35-mesothelioma samples collected 17 grew in vitro and only 4 in vivo. Two patients included in this study were at an advanced stage of MM, requiring only biopsy for the diagnosis. From two patients was obtained a portion of the resected malignant pleura sufficiently large to be able to undergo both in vitro cell culture and a portion was fixed in 10% buffered formalin and processed for the subsequent histological analysis. Tumor samples were obtained in sterile conditions avoiding apparently necrotic and fibrotic areas. The 4 patients, all male, underwent surgery or biopsy for the first time and never received chemotherapy or radiotherapy; all the sample were diagnosed as epithelioid MM. Tumor samples were immediately processed by mechanical disgregation and plated on gelatin coated flasks (Sigma, Saint Louis, MO, USA) in MCDB (Sigma), 2 mM L-glutamine (Gibco Ltd, Paisley, Scotland), recombinant human bFGF (10 ng/ml, Peprotech, London, UK), recombinant human EGF (20 ng/ml, Peprotech), 15 μg/ml insulin, 2 μg/ml heparin and 2% FBS (Euroclone, Devon UK). For subculture, 0.25% trypsin-EDTA (Euroclone, Devon UK) was used. If stromal cell growth was noted during initial growth, differential trypsinization was used to obtain a pure tumor cell population. The method is based on the treatment of the culture with trypsin for around 1 minute, with continuous microscopic observation. When the fibroblasts detach but the epithelial cells are still adherent the enzyme is inactivated with FCS containing medium. Pure populations of MM cells were obtained after three to four passages. All cell cultures showed the monolayer growth pattern, and population doubling times ranged from 63 to 68 hours. Cultured cells were frozen in 10% dimethylsulfoxide in fetal calf serum and stored in liquid nitrogen. The four cell cultures were used between the eighth and twelfth passage in culture.
Cells of all patients were plated on gelatin coated glass coverslips and then fixed with 4% paraformaldehyde, treated with PBS 10% NGS 0.5% triton X100 and then stained with the anti-SOX2 antibody (Chemicon, Temecula, CA, USA) followed by goat anti-mouse IgG (Alexa 488, Molecular Probes, Oslo, Norway) or rhodamine-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA, USA). The cells were counterstained with Hoechst 33342 dye (Sigma) to identify nuclei.
Tumors cryosections were fixed in 4% PFA. Antibody staining was carried out following heat induced antigen retrieval using citrate buffer (pH 6.1) and with permeabilization in PBS containing 0.1% Triton X-100 and blocked in 10% normal Goat serum-PBS. After incubation with anti-Mesothelin antibody (Zymed Laboratories, San Francisco, CA, USA), sections were stained with the appropriate secondary antibodies and counterstained with Hoechst 33342 dye (Sigma) to identify all nuclei.
MM xenografts and serial transplantation
103-106 MM primary cells were intraperitoneally (i.p.) injected in 4-6 weeks old NOD-SCID mice (Charles River, Milan, Italy) to test their ability to grow in vivo. After several weeks cell growth was detected by the development of obvious ascites. In-vivo grown cells were harvested by intraperitoneal washing. A portion of the above-recovered tumor cells were injected i.p. into secondary NOD/SCID mice. Serial transplantation was carried out every two months until the fifth passage, using four mice per group. Mice were monitored for disease symptoms and were sacrificed by CO2 asphyxiation when ascites caused respiratory distress or they became extremely weak. All experiments were performed in compliance with guidelines approved by the Ethical Committee for animal use in cancer research at Istituto Nazionale Ricerca Cancro - Genova.
For xenograft tumor analysis, tumor masses grown in vivo were collected from sacrificed mice, cryopreserved and 10-μm cryostat (Leica, Wetzlar, Germany) sections were cut. For WT-1 (Dako Cytomation, Denmark) staining, tumors cryosections were fixed in 4% PFA, treated with 0.4% pepsin in 0.2 N HCl, then with 3% H2O2-PBS protect from light, permeabilized in PBS 10% NGS 0.5% Triton X-100, incubated with primary antibody and then stained with anti-mouse EnVision-HRP (Dako). Signal was revealed with AEC substrate (Sigma).
For Calretinin (Dako) staining, sections were fixed in 4% PFA, then antibody staining was carried out following heat induced antigen retrieval using 10 mM Tris-Cl 1 mM EDTA pH9 and treatment with 0.3% H2O2-PBS protect from light. Cryosections were permeabilized in PBS 10% NGS 0.5% Triton X-100, incubated with primary antibody and then with biotynilated affinity-purified goat anti-mouse (BIOSPA, Milano Italy). Expression was detected using streptavidin/horseradish peroxidase (Jackson Immunoresearch). Signal was revealed with Chromogen 3-amino-9-ethylcarbazole (AEC) substrate.
For D2-40 staining (Dako), cryosections were fixed in 4% PFA, then antibody staining was carried out following heat induced antigen retrieval using Target Retrival Solution S1700 (Dako) and treatment with 3% H2O2-PBS protect from light. Cryosections were permeabilized in PBS 10% NGS 0.3% Triton X-100, incubated with primary antibody and then stained with anti-mouse EnVision-HRP and counterstained with Harris's Ematossilin (Bio-Optica). Signal was revealed with AEC substrate. Mouse IgG was used as a negative control for all the tissues. Digital images were captured by a Nikon Eclipse 80 i microscope (Nikon Europe, Lijnden, The Netherlands).
Flow cytofluorimetric analysis
For cytofluorimetric analysis cultured MM cells were stained with the appropriate amount of PE or FITC-conjugated mAbs or PE or FITC- conjugated isotype-specific control antibody. MM cells were stained with the following antibodies: CD31, CD68, CD141, CD56, CD63, CD86, CD30, CD11b, CD46, CD184, EGFR, CD24, CD90, CD55, CD47, CD99, CD140b (BD Bioscience, San Jose, CA). 10,000 labeled cells were acquired and analyzed using a FACScan flow cytometer running CellQuest software (Becton Dickinson & Co, Mountain View, CA).
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Milan, Italy), retrotranscribed using iScriptTM cDNA Synthesis Kit (Bio-Rad, Milano, Italy) and amplified with iQ Syber Green SuperMix (Bio-Rad) by PCR (iCYCLER, Bio-Rad) using the following primers: Nanog (forward 5'gaactctccaacatcctgaacctc3', reverse 5'ccttctgcgtcacaccattgc 3'), OCT4 (forward 5'tgtctccgtcaccactctg3', reverse 5'ctttctgttcccaattccttcc3'), Sema3A (forward 5'ggcatataatcagactcacttgtacgc3', reverse 5'cttgcatatctgacctattctagcgtg3'), NCAM2 (forward 5'agtggctccagtggcaaa3', reverse 5'ggctcccatcttcgtgatta3'), PDGFd (forward 5'aatgatgatgccaagcgttac3', reverse 5'gacctccagttgacagttcc3'), ABCA6 (forward 5'ggcaggcaatccaggcagtc3', reverse 5'acacggtcacacaaggcttcc3'), PDGFRb (forward 5'gtcctgcctgtccttctac3', reverse 5'tgtccttgctgctgatgg3'), DKK1 (forward 5'agtccttctgagatgatgg3', reverse 5'ggttcttgatagcgttgg3'), Mesothelin (MSTN) (forward 5'ggcacagaagaatgtcaag3', reverse 5'atagcagcaggtccaatg3'), calretinin (CALB2) (5'aacttccttctgtgcttc3', reverse 5'tatggtttgggtgtattcc3'). Samples were normalized using L41 primers (forward 5'agtggaggaagaagcgaatg3', reverse 5'tttatgagcaaggtgggtctc3'). The four primary cell cultures were analyzed together with positive and negative controls. Data presented here are means of biological and technical duplicates.
Metaphases for cytogenetic analysis were prepared from the first xenograft of the MM cell cultures. Chromosome preparations were obtained by standard cytogenetic techniques. For Q-banding metaphase spreads were stained by 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) and counterstained with actinomycin D (Sigma-Aldrich)  (Scheizer 1994). and karyotyped according to the International System for Human Cytogenetic Nomenclature  (Shaffer LG, 2005) using the Cytovision Karyotyping software (Applied Imaging, Newcastle-upon-Tyne, UK).
Establishment of human MM cell cultures
In vivogrowth of human MM cell cultures
Survival time of mice serially transplanted.
180 ± 20
130 ± 6
117 ± 3
76 ± 8
150 ± 16
122 ± 8
80 ± 5
70 ± 12
210 ± 28
105 ± 11
150 ± 15
41 ± 6
84 ± 8
92 ± 5
MM cells expression analysis
Q-banding karyotypes of the four MM cell cultures recovered form primary transplants.
39-40, XY dic(1;4)(p12;q31), t(1;19)(p13;p13.1),2, del(2)(p21), del(3)(p14), del(3)(q13), del(6)(q14q22),-8, del(10)(q2425), der(11)t(11;18)(q23;q11.2), der(12)t(12;?)(q22;?), -13,-13,-14,-15,-17,-18,-18,+4-5 m [3cp]; 76-77, XXYY idemx2 [2cp]
71-102, XXY der(1)dup(p13p32)inv(q12p33)x2,-2, t(3;?)(p0;?), i(3q),-4,+5,-8, del(9)(p21),-9,11, der(12) del(12)(p13)t(12;?)(q24;?)x2, der(13)t(13;?)(p0;?),-13,-14,-15,-16,-17,-18,-19-20,-21,+10 m [4cp]
58-78, XX-Y, i(1)(q0),-1, der(3)t(3;12)(q0;p0), del(4)(q32),-4,-5, del(6)(q16q21), -6,-7,-8,-9, del(10)(q24q26),+11,-12,-13,-14,-15,-16,-18,-22,+5-10 m [5cp]
36-37, XY del(1)(p32), t(1;11)(p32;q22)dup(11)(q14q22), del(3)(p21), t(3;22)(q11.2;q13),-4,-5, add(6) (q27),-8,-9,-9,+der(12)dup(12)(q21),-14,-14,-15,-15,-16,-17,17, i(18q), der(19)t(19;?)(q13.2;?), add(21)(p12),+1-6 m [3cp]
The development of tumor cell lines has been an important tool in establishing suitable in vitro models for studying the biological properties of many tumors. All mesothelioma cell lines derived so far were established in-high serum growth media. Tumor cells expanded under such conditions, however, often display phenotypic characteristics and genetic aberrations due to the long term in vitro culture in the presence of calf serum and are very different to those found within the corresponding primary human tumor, also in their gene expression profile.
We have derived and characterized four human mesothelioma cell cultures that retain tumor initiating cell properties, using the chemically defined medium MCDB201 supplemented with 2% FCS, EGF and FGF. A low serum medium and selected mitogens were used for their known ability to encourage self-renewal by preventing in vitro commitment to differentiation, and to preserve the ability to form tumors in immunodeficient mice that recapitulate the heterogeneity normally seen on human cancers [16, 21].
The growth and morphological properties of these new established mesothelioma cell cultures are heterogeneous. Some of them grow as fairly firmly attached monolayers whereas others grow as both floating and loosely attached cultures.
The MM1-4 cell cultures described here are able to engraft after pseudo orthotopic intraperitoneal transplantation in immunodeficient mouse, where they mainly grow as free floating cells that eventually aggregate, recapitulating a characteristic that is thought to be typical of normal mesothelial stem/progenitor cells . When as low as 1000 cells were injected the tumor take rate was not affected, indicating that our cell cultures are highly enriched in tumor initiating cells when compared to the other available MM cell lines, which require at least 106 cells to obtain the same take rate . Their ability to engraft after serial transplantation is a hallmark of tumor initiating cells. The faster development of tumor after serial transplantation may be due to a progressive increase of the TICs fraction or to an in vivo selection of the more aggressive cells. To avoid this selection of fast proliferating cells and to completely deplete the contaminating fibroblasts present in primary cultures, all the experiments were performed with cells recovered from the first xenograft. To determine whether MM cell cultures display genomic alterations characteristic of mesothelioma, we performed cytogenetic analyses of the cell cultures recovered from primary xenografts. The results confirmed their human origin and showed many and varied structural and numeric abnormalities. The disease develops for decades, during which the neoplastic cells accumulate a variety of chromosomal aberrations. Cytogenetic analysis revealed rearrangement of the short arm of chromosome 1, an aberration frequently reported in mesothelioma karyotypes (56% of the cases), as well as rearrangements of the short arm of chromosome 3 that are found in 51% of the cases, deletion accounting for nearly half of them (48%). Sandberg and Bridge  proposed a scheme for the stepwise process of genetic changes leading to the full development of malignant mesothelioma. In this scheme a deletion in the short arm of chromosome 3 is a late event and deletion of chromosome 1 is mainly found in metastatic tumors.
In order to better characterize the MM cell cultures we performed a phenotypic characterization by FACS analysis using antibodies against membrane proteins. Among the surface markers known to be expressed by mesothelioma cell lines, our cell cultures were strongly positive for CD46 , CD47 , CD56  and CD63 , while showed a variable positivity for CD140b  and CD141 . The four MM cell cultures were also strongly positive for some markers never described before in mesothelioma cell lines, including CD55, CD90 and CD99 that may represent new markers potentially useful for the isolation of cancer stem cells from MM. CD55 together with CD46 are complement regulatory proteins. Cells that express complement regulatory proteins are able to modulate their sensitivity to complement-mediated lysis and their ability to survive into a proinflammatory environment in which C3 activation frequently occurs. It has been demonstrated that a reduction in CD46 results in increased C3b deposition on apoptotic cells, which are then killed by macrophages. The complement-regulatory proteins are also able to regulate T cell function inhibiting the immune response against cancer. CD55 was also found expressed on side-population (SP) cells of mammary carcinoma cell lines and used for isolation of cancer stem cells. Cells expressing high level of CD55 were resistant to apoptosis induced by serum depletion as in the case of SP cells. The identification of CD90 on our cells, a marker known to be expressed on subsets of hematopoietic and non-hematopoietic stem cells, raises the possibility that CD90 expression identifies a highly proliferative and/or stem cell-like component of these neoplasm. CD90 is also expressed on mesenchymal stem cells and fibroblasts not committed to adipogenesis.
Immunoreactivity of CD99 was detected in invasive malignant melanoma, in pancreatic endocrine tumors, Ewing's sarcoma and gastric cancer. A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells, in osteosarcoma and prostate cancer. In osteosarcoma and prostate cancer, cells overexpressing the long CD99wt isoform inhibited and delayed formation of lung or bone metastases. The high level of CD99 on MM cells may explain the absence of long distance metastasis.
CD140b (PDGFRβ) is of special interest since the a subunit of the receptor is predominantly expressed in benign mesothelial cells, whereas expression of the β subunit is found in MM cell lines and clinical specimens . An inverse correlation between the expression of PDGFRb and PDGFd was observed on our MM cells. This observation suggests that cells expressing low levels of receptor needs to produce high levels of ligand, supporting the importance of this autocrine pathway in MM, a possible therapeutic target.
By real time PCR we found that our cell cultures expressed high mRNA levels of typical mesothelioma markers as mesothelin (MSLN) and calretinin (CALB2), of BMI-1, a stemness marker and of DKK1, a potent Wingless [WNT] inhibitor. It is interesting to note that, in a previous report , DKK1 was used to induce apoptosis of MM cells by antagonizing Wnt signaling independently of β-catenin. Our cell cultures express DKK1 at high levels, like other tumors such as Wilms' tumor, osteosarcomas, hepatocellular carcinomas and prostate cancer [34–36]. It is already known that Wnt signaling is an osteoinductive signal that promotes differentiation of osteo-progenitors and that, in human mesenchymal stem cell the inhibition of Wnt signaling with recombinant soluble DKK1 induces spontaneous transformation and tumorigenicity . Other reports indicates that sustained Wnt signaling inhibits neural differentiation while inducing differentiation along meso/endoderm lineages in human and mouse embryonic stem cells . It is therefore conceivable to hypothesize that mesothelium belongs to the developmental lineage group of cells that are induced to differentiate by Wnt signaling. Thus, the inhibitory effect of DKK1 would maintain stemness and inappropriate persistent DKK1 and BMI-1 expression would ultimately lead to malignant transformation, by keeping the cells in an undifferentiated, "stem-like" cellular state.
In conclusion, this paper describes the establishment and characterization of four new mesothelioma cell cultures derived from male patients that never received chemotherapy or radiotherapy. Our cells, cultured under stemness conditions, are able to survive and grow in low serum conditions, although at a slower rate than that observed under high serum conditions. When transplanted into immunodeficient mice these cells are able to engraft and form tumors that are phenocopies of the original tumor. The cells expressed mesothelioma markers together with some typical genes involved in stemness such as BMI-1 and CD90. The expression of these stem cell markers may reflect the presence in these cultures of a higher proportion of TICs compared to the mesothelioma cell lines available to date which have been kept in high serum media and passaged for long periods. This higher "stemness" is supported by the fact that 103 cells are able to achieve 100% tumor take, a thousand-fold less than required by the other available MM cell lines. For these reasons, these MM cell cultures may provide a valuable in vitro and in vivo model to study the biology of this poorly understood deadly tumor.
This work was supported by Buzzi Foundation for the study of MesotheliomaThe authors thank Dr. Caterina Casadio, Dr. Gianfranco Tassi and Dr. Rosangela Filiberti for providing tumor samples and Dr. Bharat Jasani for providing valuable suggestions.
- Simsir A, Fetsch P, Bedrossian CW, Ioffe OB, Abati A: Absence of SV-40 large T antigen (Tag) in malignant mesothelioma effusions: an immunocytochemical study. Diagn Cytopathol. 2001, 25 (4): 203-207. 10.1002/dc.2039.View ArticlePubMedGoogle Scholar
- Bocchetta M, Di Resta I, Powers A, Fresco R, Tosolini A, Testa JR, Pass HI, Rizzo P, Carbone M: Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci USA. 2000, 97 (18): 10214-10219. 10.1073/pnas.170207097.View ArticlePubMedPubMed CentralGoogle Scholar
- Cristaudo A, Foddis R, Vivaldi A, Buselli R, Gattini V, Guglielmi G, Cosentino F, Ottenga F, Ciancia E, Libener R, et al: SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res. 2005, 65 (8): 3049-3052.PubMedGoogle Scholar
- Ismail-Khan R, Robinson LA, Williams CC, Garrett CR, Bepler G, Simon GR: Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006, 13 (4): 255-263.PubMedGoogle Scholar
- West SD, Lee YC: Management of malignant pleural mesothelioma. Clin Chest Med. 2006, 27 (2): 335-354. 10.1016/j.ccm.2006.01.004.View ArticlePubMedGoogle Scholar
- Manning LS, Whitaker D, Murch AR, Garlepp MJ, Davis MR, Musk AW, Robinson BW: Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer. 1991, 47 (2): 285-290. 10.1002/ijc.2910470219.View ArticlePubMedGoogle Scholar
- Orengo AM, Spoletini L, Procopio A, Favoni RE, De Cupis A, Ardizzoni A, Castagneto B, Ribotta M, Betta PG, Ferrini S, et al: Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J. 1999, 13 (3): 527-534. 10.1183/09031936.99.13352799.View ArticlePubMedGoogle Scholar
- Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, Mew DJ, Pogrebniak HW, Matthews WJ: Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg. 1995, 59 (4): 835-844. 10.1016/0003-4975(95)00045-M.View ArticlePubMedGoogle Scholar
- Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, Yokoi K, Horio Y, Shimokata K, Sekido Y, et al: Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006, 97 (5): 387-394. 10.1111/j.1349-7006.2006.00184.x.View ArticlePubMedGoogle Scholar
- Zeng L, Fleury-Feith J, Monnet I, Boutin C, Bignon J, Jaurand MC: Immunocytochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies. Hum Pathol. 1994, 25 (3): 227-234. 10.1016/0046-8177(94)90192-9.View ArticlePubMedGoogle Scholar
- Dalerba P, Cho RW, Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med. 2007, 58: 267-284. 10.1146/annurev.med.58.062105.204854.View ArticlePubMedGoogle Scholar
- Cho RW, Clarke MF: Recent advances in cancer stem cells. Curr Opin Genet Dev. 2008, 18 (1): 48-53. 10.1016/j.gde.2008.01.017.View ArticlePubMedGoogle Scholar
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100 (7): 3983-3988. 10.1073/pnas.0530291100.View ArticlePubMedPubMed CentralGoogle Scholar
- Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997, 3 (7): 730-737. 10.1038/nm0797-730.View ArticlePubMedGoogle Scholar
- Singh SK, Clarke ID, Hide T, Dirks PB: Cancer stem cells in nervous system tumors. Oncogene. 2004, 23 (43): 7267-7273. 10.1038/sj.onc.1207946.View ArticlePubMedGoogle Scholar
- Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al: Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006, 9 (5): 391-403. 10.1016/j.ccr.2006.03.030.View ArticlePubMedGoogle Scholar
- Schweizer D, Ambros PF: Chromosome banding. Stain combinations for specific regions. Methods Mol Biol. 1994, 29: 97-112.PubMedGoogle Scholar
- Shaffer LGTN: ISCN 2005: An International System for Human Cytogenetic Nomenclature. 2005, Basel, Switzerland: KargerGoogle Scholar
- Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM: Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med. 1982, 96 (6 Pt 1): 746-755.View ArticlePubMedGoogle Scholar
- Hillerdal G: Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest. 1983, 77 (4): 321-343. 10.1016/0007-0971(83)90068-2.View ArticlePubMedGoogle Scholar
- Griffero F, Daga A, Marubbi D, Capra MC, Melotti A, Pattarozzi A, Gatti M, Bajetto A, Porcile C, Barbieri F, et al: Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem. 2009, 284 (11): 7138-7148. 10.1074/jbc.M807111200.View ArticlePubMedPubMed CentralGoogle Scholar
- Herrick SE, Mutsaers SE: Mesothelial progenitor cells and their potential in tissue engineering. Int J Biochem Cell Biol. 2004, 36 (4): 621-642. 10.1016/j.biocel.2003.11.002.View ArticlePubMedGoogle Scholar
- Bertino P, Piccardi F, Porta C, Favoni R, Cilli M, Mutti L, Gaudino G: Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res. 2008, 14 (2): 541-548. 10.1158/1078-0432.CCR-07-1388.View ArticlePubMedGoogle Scholar
- Mitelman Database of Chromosome Aberrations in Cancer (2009): Edited by: Mitelman F, Johansson B, Mertens F. Accessed on 2009, [http://cgap.nci.nih.gov/Chromosomes/Mitelman]
- Sandberg AA, Bridge JA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma. Cancer Genet Cytogenet. 2001, 127 (2): 93-110. 10.1016/S0165-4608(01)00432-0.View ArticlePubMedGoogle Scholar
- Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M: Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res. 2008, 68 (12): 4882-4892. 10.1158/0008-5472.CAN-07-6265.View ArticlePubMedGoogle Scholar
- Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ, et al: Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 2005, 166 (6): 1827-1840.View ArticlePubMedPubMed CentralGoogle Scholar
- Lantuejoul S, Laverriere MH, Sturm N, Moro D, Frey G, Brambilla C, Brambilla E: NCAM (neural cell adhesion molecules) expression in malignant mesotheliomas. Hum Pathol. 2000, 31 (4): 415-421. 10.1053/hp.2000.6552.View ArticlePubMedGoogle Scholar
- Hegmans JP, Bard MP, Hemmes A, Luider TM, Kleijmeer MJ, Prins JB, Zitvogel L, Burgers SA, Hoogsteden HC, Lambrecht BN: Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol. 2004, 164 (5): 1807-1815.View ArticlePubMedPubMed CentralGoogle Scholar
- Kothmaier H, Quehenberger F, Halbwedl I, Morbini P, Demirag F, Zeren H, Comin CE, Murer B, Cagle PT, Attanoos R, et al: EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax. 2008, 63 (4): 345-351. 10.1136/thx.2007.085241.View ArticlePubMedGoogle Scholar
- Ordonez NG: Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med. 2005, 129 (11): 1407-1414.PubMedGoogle Scholar
- Versnel MA, Claesson-Welsh L, Hammacher A, Bouts MJ, Kwast van der TH, Eriksson A, Willemsen R, Weima SM, Hoogsteden HC, Hagemeijer A, et al: Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene. 1991, 6 (11): 2005-2011.PubMedGoogle Scholar
- Lee AY, He B, You L, Xu Z, Mazieres J, Reguart N, Mikami I, Batra S, Jablons DM: Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun. 2004, 323 (4): 1246-1250. 10.1016/j.bbrc.2004.09.001.View ArticlePubMedGoogle Scholar
- Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET: Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate. 2008, 68 (13): 1396-1404. 10.1002/pros.20805.View ArticlePubMedPubMed CentralGoogle Scholar
- Patil MA, Chua MS, Pan KH, Lin R, Lih CJ, Cheung ST, Ho C, Li R, Fan ST, Cohen SN, et al: An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene. 2005, 24 (23): 3737-3747. 10.1038/sj.onc.1208479.View ArticlePubMedGoogle Scholar
- Wirths O, Waha A, Weggen S, Schirmacher P, Kuhne T, Goodyer CG, Albrecht S, Von Schweinitz D, Pietsch T: Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest. 2003, 83 (3): 429-434.View ArticlePubMedGoogle Scholar
- Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar MA, Singer S, Maki RG, Cordon-Cardo C: Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest. 2007, 117 (11): 3248-3257. 10.1172/JCI31377.View ArticlePubMedPubMed CentralGoogle Scholar
- Bakre MM, Hoi A, Mong JC, Koh YY, Wong KY, Stanton LW: Generation of multipotential mesendodermal progenitors from mouse embryonic stem cells via sustained Wnt pathway activation. J Biol Chem. 2007, 282 (43): 31703-31712. 10.1074/jbc.M704287200.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/54/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.